SEB Asset Management AB Makes New $134.14 Million Investment in Cencora, Inc. $COR

SEB Asset Management AB acquired a new position in shares of Cencora, Inc. (NYSE:COR) during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 427,004 shares of the company’s stock, valued at approximately $134,139,000. Cencora accounts for about 0.6% of SEB Asset Management AB’s investment portfolio, making the stock its 27th biggest holding.

A number of other large investors have also made changes to their positions in COR. Kemnay Advisory Services Inc. bought a new stake in shares of Cencora in the fourth quarter valued at about $25,000. Oakworth Capital Inc. acquired a new stake in Cencora during the fourth quarter worth about $26,000. Elyxium Wealth LLC bought a new position in Cencora during the fourth quarter valued at about $27,000. Archer Investment Corp increased its stake in Cencora by 134.3% during the fourth quarter. Archer Investment Corp now owns 82 shares of the company’s stock valued at $28,000 after acquiring an additional 47 shares during the period. Finally, Motiv8 Investments LLC acquired a new position in Cencora in the 4th quarter valued at approximately $29,000. Institutional investors and hedge funds own 97.52% of the company’s stock.

Cencora Stock Down 0.1%

Shares of COR opened at $307.72 on Friday. The company has a quick ratio of 0.59, a current ratio of 0.95 and a debt-to-equity ratio of 3.40. The company has a 50-day moving average price of $279.98 and a two-hundred day moving average price of $317.68. The stock has a market cap of $59.87 billion, a price-to-earnings ratio of 23.60, a P/E/G ratio of 1.71 and a beta of 0.58. Cencora, Inc. has a 12 month low of $244.82 and a 12 month high of $377.54.

Cencora (NYSE:COR) last released its quarterly earnings data on Wednesday, May 6th. The company reported $4.75 earnings per share for the quarter, missing the consensus estimate of $4.82 by ($0.07). Cencora had a net margin of 0.78% and a return on equity of 135.20%. The company had revenue of $78.36 billion during the quarter, compared to the consensus estimate of $81.09 billion. During the same quarter in the prior year, the company posted $4.42 earnings per share. The company’s revenue for the quarter was up 3.9% on a year-over-year basis. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. Equities analysts predict that Cencora, Inc. will post 17.79 EPS for the current fiscal year.

Cencora announced that its board has authorized a stock buyback program on Thursday, May 21st that permits the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization permits the company to buy up to 3.9% of its shares through open market purchases. Shares repurchase programs are often an indication that the company’s board believes its shares are undervalued.

Cencora Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, June 1st. Investors of record on Friday, May 15th were paid a $0.60 dividend. The ex-dividend date of this dividend was Friday, May 15th. This represents a $2.40 annualized dividend and a yield of 0.8%. Cencora’s payout ratio is currently 18.40%.

Insiders Place Their Bets

In related news, Director Lauren M. Tyler purchased 550 shares of the stock in a transaction on Monday, June 22nd. The shares were purchased at an average cost of $270.23 per share, for a total transaction of $148,626.50. Following the completion of the transaction, the director directly owned 4,359 shares of the company’s stock, valued at approximately $1,177,932.57. The trade was a 14.44% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.38% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

COR has been the subject of a number of research reports. Bank of America raised their price objective on Cencora from $280.00 to $285.00 and gave the stock a “neutral” rating in a research report on Wednesday, June 24th. Evercore set a $360.00 target price on Cencora in a research note on Wednesday, April 8th. Robert W. Baird reduced their target price on Cencora from $420.00 to $339.00 and set an “outperform” rating for the company in a research report on Thursday, May 7th. Wells Fargo & Company reduced their target price on Cencora from $429.00 to $331.00 and set an “overweight” rating for the company in a research report on Monday, May 11th. Finally, Morgan Stanley set a $342.00 price target on shares of Cencora in a research note on Friday, May 8th. Eleven analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $367.75.

Cencora Company Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.